Translational Research and Interventional Oncology Research Program
The Translational Research and Interventional Oncology Research Program is an integrated multi-disciplinary program that provides the opportunity for clinical investigators and laboratory scientists to collaboratively address the rapidly changing landscape of cancer therapy. The program traverses multiple disciplines, including precision oncology, immuno-oncology, cellular therapy, and immune-toxicity.
The Translational Research and Interventional Oncology program is dedicated to translating our understanding of the molecular mechanisms of oncogenesis and tumor progression into novel therapeutic strategies for patients with cancer.
Early Phase Trials
Developing early phase clinical trials for therapies directed at genetic changes in tumors and for novel immunotherapeutic combinations
Investigating why some tumors become resistant to immunotherapies and genetically targeted therapies and developing new strategies to prevent and overcome resistance
Immune & Cellular Therapy
Applying and enhancing innovative immunotherapeutic strategies and cellular therapies for cancer
Meet the Program Members
The Translational Research and Interventional Oncology Program is the largest of the cancer center's formal research programs, representing a range of clinical and translational cancer research areas. The program is led by Young Kim, M.D., Ph.D. and Christine M. Lovly, M.D., Ph.D.
Abatacept for severe immune checkpoint inhibitor-associated myocarditis.
Salem, J.E., Allenbach, Y., Vozy, A., Brechot, N., Johnson, D.B. (TR), Moslehi, J.J. (TR) & Kerneis, M.
N Engl J Med 380(24):2377-2379, 2019; PMID:31189043.
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Horn L (TR), Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE
J. Clin. Oncol. 2017 DEC 10 35(35):3924-3933 PMID:29023213
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD (GI, TR)
J. Clin. Oncol. 2017 OCT 10 35(29):3338-3346 PMID:28817371
Myocarditis with Immune Checkpoint Blockade
Moslehi JJ (TR), Johnson DB (TR), Sosman JA.
N. Engl. J. Med. 2017 JAN 19 376(3):292 PMID:28099832
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
Johnson DB (TR), Balko JM (BC), Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky D (TR), Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM (NP), Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Anders RA, Sosman JA, Moslehi JJ (TR).
N. Engl. J. Med. 2016 NOV 3 375(18):1749-1755 PMC5247797
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
Moslehi JJ (TR).
N. Engl. J. Med. 2016 OCT 13 375(15):1457-1467 PMID:27732808
Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer.
Qiao H, Lovly CM (TR).
Cancer Discov 2016 OCT 6(10):1084-1086 PMC5117458.